Johnson & Johnson (JNJ) entered a merger agreement on January 13, 2025, to acquire drugmaker Intra-Cellular Therapies, Inc. (ITCI) in an all-cash deal valued at $14.6 billion.
Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies for a payment of $132.00 per share in cash, representing a premium of 39.14% from the stock’s last close.